Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Non Operating Income (2022 - 2025)

Verrica Pharmaceuticals has reported Other Non Operating Income over the past 4 years, most recently at -$889000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 5329.41% year-over-year to -$889000.0; the TTM value through Mar 2026 reached -$856000.0, down 423.02%, while the annual FY2025 figure was -$3000.0, N/A changed from the prior year.
  • Other Non Operating Income for Q4 2025 was -$889000.0 at Verrica Pharmaceuticals, down from $34000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $254000.0 in Q1 2025 and troughed at -$889000.0 in Q4 2025.
  • A 4-year average of -$51083.3 and a median of -$1000.0 in 2022 define the central range for Other Non Operating Income.
  • On a YoY basis, Other Non Operating Income climbed as much as 3500.0% in 2025 and fell as far as 5329.41% in 2025.
  • Year by year, Other Non Operating Income stood at $5000.0 in 2022, then surged by 600.0% to $35000.0 in 2023, then plummeted by 51.43% to $17000.0 in 2024, then tumbled by 5329.41% to -$889000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for VRCA at -$889000.0 in Q4 2025, $34000.0 in Q3 2025, and -$1000.0 in Q2 2025.